Antibacterial activity of imipenem-encapsulated chitosan/HPMCP nanoparticles against clinical Acinetobacter baumannii isolates.
- 1Department of Microbiology, Kaz.C., Islamic Azad University, Kazerun, Iran.
- 2Department of Microbiology, Zand Institute of Higher Education, Shiraz, Iran. [email protected].
- 3Department of Microbiology, Shi.C., Islamic Azad University, Shiraz, Iran.
Abstract
Background
Multidrug-resistant Acinetobacter baumannii is an important healthcare-associated pathogen, necessitating therapeutic strategies. This study evaluates the antibacterial efficacy of imipenem-encapsulated chitosan/hydroxypropyl methylcellulose phthalate (Imp-Chi) nanoparticles against clinical A. baumannii isolates.Methods
A. baumannii clinical isolates (n = 105) from hospitalized patients were characterized for antibiotic resistance via broth microdilution and classified as MDR, XDR, or PDR. An exploratory PCR screen was performed for the selected AmpC-family genes mox, cit, and dha. Imp-Chi nanoparticles were synthesized via ionic gelation, characterized for size, zeta potential, morphology, encapsulation efficiency, and drug release. Antibacterial activity was assessed via MIC assays against the A. baumannii clinical isolates. Recoverable bacterial burden in extracellular, cell-associated, and intracellular fractions of A549 and NCI-H292 infection models was quantified, alongside reactive oxygen species (ROS) and cytotoxicity assessments using MTT and LDH assays.Results
Isolates exhibited high resistance to β-lactams (97.1-99.0%), carbapenems (94.3-98.1%), and aminoglycosides (92.4-96.2%), with 77.1% classified as PDR. No significant association was observed between the selected AmpC-family genes and resistance phenotypes (p > 0.05). Imp-Chi nanoparticles (291.3 nm, + 34.9 mV; spherical morphology with smooth surfaces) demonstrated optimal encapsulation efficiency (1.5 µg imipenem) and sustained drug release (70% over 10 h). MICs of Imp-Chi nanoparticles were significantly lower than free imipenem (p < 0.0001; ~0.31-fold reduction); while fractional inhibitory concentration index values clustered around 1.0, supporting an additive or near-additive rather than synergistic interaction, and the nanoparticles also reduced recoverable bacterial CFU across extracellular and host-cell-associated fractions in lung epithelial infection models in vitro. ROS levels in A. baumannii-infected cells decreased to near-baseline levels following Imp-Chi treatment (p < 0.0001). MTT and LDH readouts suggested limited cytotoxicity-associated effects at 100-200 µg/mL and concentration-dependent effects at higher concentrations, with apparent MTT-derived IC₅₀ values of approximately 740 µg/mL; however, nanoparticle-related assay interference and carrier-specific effects were not independently excluded.Conclusions
Imp-Chi nanoparticles reduced imipenem MICs through additive or near-additive antibacterial contributions and may also provide formulation-related delivery advantages, while reducing bacterial burden in lung epithelial infection models and being associated with lower infection-associated ROS levels in vitro.Clinical trial number
Not applicable.
Related
- Chitosan polymeric nanoparticles loaded with a grapefruit-derived flavonoid-rich extract containing naringenin: antibacterial activity, cytotoxicity evaluation and DFT interaction analysis
- Outbreak of carbapenem-resistant Acinetobacter baumannii in post–haematopoietic stem cell transplantation patients potentially caused by drinking water contamination
- Community-acquired Acinetobacter baumannii pneumonia in Southern Vietnam : A retrospective cohort study
- Validation of NG-TEST Acineto-5 for the Detection of OXA Carbapenemases, NDM, and VIM in the Acinetobacter calcoaceticus-baumannii Complex and beyond
- Natural polysaccharide-engineered POP@ZIF-67 nanoparticles coordinate antibacterial activity, macrophage polarization, and osteogenesis for chronic osteomyelitis therapy.
BibTeX
@article{alizadeh2026antibacterial,
title = {{Antibacterial activity of imipenem-encapsulated chitosan/HPMCP nanoparticles against clinical Acinetobacter baumannii isolates.}},
author = {Sajad Alizadeh and Majid Baseri Salehi and Nima Bahador},
journal = {BMC infectious diseases},
year = {2026},
month = jul,
doi = {10.1186/s12879-026-13962-8},
url = {https://europepmc.org/article/MED/42919155},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Antibacterial activity of imipenem-encapsulated chitosan/HPMCP nanoparticles against clinical Acinetobacter baumannii isolates.
AU - Sajad Alizadeh
AU - Majid Baseri Salehi
AU - Nima Bahador
PY - 2026
DA - 2026/07/01
JO - BMC infectious diseases
DO - 10.1186/s12879-026-13962-8
UR - https://europepmc.org/article/MED/42919155
AB - Background Multidrug-resistant Acinetobacter baumannii is an important healthcare-associated pathogen, necessitating therapeutic strategies. This study evaluates the antibacterial efficacy of imipenem-encapsulated chitosan/hydroxypropyl methylcellulose phthalate (Imp-Chi) nanoparticles against clinical A. baumannii isolates.Methods A. baumannii clinical isolates (n = 105) from hospitalized patients were characterized for antibiotic resistance via broth microdilution and classified as MDR, XDR, or PDR. An exploratory PCR screen was performed for the selected AmpC-family genes mox, cit, and dha. Imp-Chi nanoparticles were synthesized via ionic gelation, characterized for size, zeta potential, morphology, encapsulation efficiency, and drug release. Antibacterial activity was assessed via MIC assays against the A. baumannii clinical isolates. Recoverable bacterial burden in extracellular, cell-associated, and intracellular fractions of A549 and NCI-H292 infection models was quantified, alongside reactive oxygen species (ROS) and cytotoxicity assessments using MTT and LDH assays.Results Isolates exhibited high resistance to β-lactams (97.1-99.0%), carbapenems (94.3-98.1%), and aminoglycosides (92.4-96.2%), with 77.1% classified as PDR. No significant association was observed between the selected AmpC-family genes and resistance phenotypes (p > 0.05). Imp-Chi nanoparticles (291.3 nm, + 34.9 mV; spherical morphology with smooth surfaces) demonstrated optimal encapsulation efficiency (1.5 µg imipenem) and sustained drug release (70% over 10 h). MICs of Imp-Chi nanoparticles were significantly lower than free imipenem (p < 0.0001; ~0.31-fold reduction); while fractional inhibitory concentration index values clustered around 1.0, supporting an additive or near-additive rather than synergistic interaction, and the nanoparticles also reduced recoverable bacterial CFU across extracellular and host-cell-associated fractions in lung epithelial infection models in vitro. ROS levels in A. baumannii-infected cells decreased to near-baseline levels following Imp-Chi treatment (p < 0.0001). MTT and LDH readouts suggested limited cytotoxicity-associated effects at 100-200 µg/mL and concentration-dependent effects at higher concentrations, with apparent MTT-derived IC₅₀ values of approximately 740 µg/mL; however, nanoparticle-related assay interference and carrier-specific effects were not independently excluded.Conclusions Imp-Chi nanoparticles reduced imipenem MICs through additive or near-additive antibacterial contributions and may also provide formulation-related delivery advantages, while reducing bacterial burden in lung epithelial infection models and being associated with lower infection-associated ROS levels in vitro.Clinical trial number Not applicable.
SN - 1471-2334
ER -